Ozempic Maker Novo Drops After First Stock Split in a Decade

Must read

5 Style Aesthetics That Will Take Over Fashion In 2023

Photo: Monica Feudi/Brandon Maxwell.Looking ahead, the fashion landscape is showing a notable range for incoming aesthetics –– there’s a moment of fantasy that’s showing...

The Under-$100 Topshop Finds R29 Editors Adore

When thinking of British fashion, a few key pieces come to mind: a trusty trench coat (Burberry, if being boujee), a chunky knit, and...

Trump’s Nightmare Comes True As House Votes To Release His Tax Returns

The House Ways and Means Committee voted 24-16 to release six years of Trump’s...

70000 Tons Of Metal Books, Then Removes VEKTOR From Its Lineup

The 70000 Tons Of Metal cruise has been announcing its lineup...

(Bloomberg) — Novo Nordisk A/S shares fell on Wednesday in the first trading session following a split aimed at increasing the liquidity of the Danish drugmaker’s soaring stock.

Most Read from Bloomberg

A broader risk-off mood weighed on sentiment after the two-for-one split, which the maker of weight-loss drugs Ozempic and Wegovy has said will bring price levels for its Copenhagen-listed shares and American Depositary Receipts “in line with market practice.”

Novo’s Split Aims for Big Tech-Like Retail Buzz: Taking Stock

Novo was down 2.3% at 665.9 Danish kroner as of 11:10 a.m. CET, trimming some of the gains which saw Novo top luxury giant LVMH as Europe’s most valuable firm last month.

The shares have risen almost sevenfold since the company last split its stock in January 2014, driven by the company’s leadership in the global market for obesity drugs, which JPMorgan Chase & Co. analyst Richard Vosser projects to be worth $71 billion within a decade. And the majority of analysts see the strength continuing.

“This is a once in a generation type of story in that this is not just a big market, but these drugs are something that have the potential to change society in meaningful ways,” said Emily Field, an analyst at Barclays Plc with an overweight rating on the stock.

Investors are optimistic too. “They are on an absolutely huge market which is growing more than twice as fast as the industry,” said Nicolas Domont, a fund manager at Optigestion who recently added to his stake. There’s “only a few things in Europe that are appealing and among them is Novo Nordisk.”

According to Domont, the stock is “expensive but not excessive,” trading at about 35 times forward earnings.

While that multiple is nearly double that of the Stoxx 600 Health Care subindex, it’s less than that of Novo’s main obesity-drug rival Eli Lilly & Co. Lilly shares trade at about 50 times forward earnings, boosted not only by its potential in weight-loss drugs but also a successful final-stage trial of its experimental treatment for Alzheimer’s disease, another hot area of the pharmaceuticals sector.

Not everyone is positive on the outlook. According to UBS Group AG analyst Michael Leuchten, the obesity revenue opportunity won’t be as big as Novo’s current valuation implies.

“It’s a race-to-arms and can you jump to the conclusion that Novo can win? I don’t think so,” Leuchten said.

Thomas Brenier, head of equity management and research at Lazard Freres Gestions said that in terms of valuation, “it is actually starting to be very, very tense.”

“It seems that we could be at a moment which is a little excessive,” he said.

(Updates with today’s share decline from first paragraph)

Most Read from Bloomberg Businessweek

©2023 Bloomberg L.P.

More articles

Latest article

Stock Market 2023: What To Do After ‘Stay Away’ Year; Tesla, Nio, BYD Deliveries Due

Dow Jones futures will open on Monday evening, along with S&P 500 futures and Nasdaq futures. Tesla (TSLA) and China EV makers such...

I AM MORBID, KATATONIA, DECAPITATED & More To Play Denmark’s Viborg Metal Festival

Viborg Metal Festival will take place between March 3 and 4 at the Musikforening Olm Viborg and Paletten venues in Viborg, Denmark. The lineup...

Chris Sewell Digital Media Delivers Global Brand Exposure by Synthesizing Technology Plus Social

Content marketing involves telling your brand's story. When you want to expand your business, content is key to helping you reach your target audience...

All The Fashion Items You Should Try This Fall, According To R29 Editors

The leaves are starting to turn and sweaters are coming out of storage. However you feel about fall, it's time to dig into some...